File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage - A long-term randomized, controlled study

TitleTreatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage - A long-term randomized, controlled study
Authors
Issue Date2000
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
Citation
American Journal Of Gastroenterology, 2000, v. 95 n. 9, p. 2225-2232 How to Cite?
AbstractOBJECTIVE: Eradication of Helicobacter pylori (H. pylori) in patients with uncomplicated duodenal ulcers prevents long-term recurrence of ulcers. We aimed to study whether treatment of H. pylori prevents the long-term recurrence of duodenal ulcer hemorrhage. METHODS: Patients with duodenal ulcer bleeding and confirmed H. pylori infection were recruited. A total of 120 patients were randomly assigned to triple therapy (DeNoltab 120 mg, amoxycillin 500 mg, and metronidazole 300 mg four times daily) or DeNoltab 120 mg four times daily alone. No maintenance therapy was given during the follow-up period. The endpoints were the cumulative rates of symptomatic and bleeding duodenal ulcer recurrences. RESULTS: Of the patients receiving the triple regimen, 85.1% had H. pylori eradicated as compared to 2.0% of patients receiving DeNoltab (p < 0.05). More patients in the DeNoltab group than those in the Triple group had recurrence of ulcer bleeding, but this did not reach statistical significance (12/60 vs 6/60, p = 0.20). Logistic regression analysis on clinical, personal, and endoscopic characteristics identified persistent H. pylori infection as the only independent predictor of recurrence of duodenal ulcer bleeding. CONCLUSIONS: Treatment of H. pylori alone with the present bismuth-based triple therapy in patients with duodenal ulcer hemorrhage did not result in significant reduction in further bleeding episodes, although a trend was seen for the group that was given triple therapy. On the other hand, posttreatment H. pylori status was found to be an independent predictor of bleeding recurrence. (C) 2000 by Am. Coll. of Gastroenterology.
Persistent Identifierhttp://hdl.handle.net/10722/162383
ISSN
2015 Impact Factor: 10.383
2015 SCImago Journal Rankings: 3.946
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, KCen_US
dc.contributor.authorHui, WMen_US
dc.contributor.authorWong, WMen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorHu, WHCen_US
dc.contributor.authorChing, CKen_US
dc.contributor.authorLam, SKen_US
dc.date.accessioned2012-09-05T05:19:28Z-
dc.date.available2012-09-05T05:19:28Z-
dc.date.issued2000en_US
dc.identifier.citationAmerican Journal Of Gastroenterology, 2000, v. 95 n. 9, p. 2225-2232en_US
dc.identifier.issn0002-9270en_US
dc.identifier.urihttp://hdl.handle.net/10722/162383-
dc.description.abstractOBJECTIVE: Eradication of Helicobacter pylori (H. pylori) in patients with uncomplicated duodenal ulcers prevents long-term recurrence of ulcers. We aimed to study whether treatment of H. pylori prevents the long-term recurrence of duodenal ulcer hemorrhage. METHODS: Patients with duodenal ulcer bleeding and confirmed H. pylori infection were recruited. A total of 120 patients were randomly assigned to triple therapy (DeNoltab 120 mg, amoxycillin 500 mg, and metronidazole 300 mg four times daily) or DeNoltab 120 mg four times daily alone. No maintenance therapy was given during the follow-up period. The endpoints were the cumulative rates of symptomatic and bleeding duodenal ulcer recurrences. RESULTS: Of the patients receiving the triple regimen, 85.1% had H. pylori eradicated as compared to 2.0% of patients receiving DeNoltab (p < 0.05). More patients in the DeNoltab group than those in the Triple group had recurrence of ulcer bleeding, but this did not reach statistical significance (12/60 vs 6/60, p = 0.20). Logistic regression analysis on clinical, personal, and endoscopic characteristics identified persistent H. pylori infection as the only independent predictor of recurrence of duodenal ulcer bleeding. CONCLUSIONS: Treatment of H. pylori alone with the present bismuth-based triple therapy in patients with duodenal ulcer hemorrhage did not result in significant reduction in further bleeding episodes, although a trend was seen for the group that was given triple therapy. On the other hand, posttreatment H. pylori status was found to be an independent predictor of bleeding recurrence. (C) 2000 by Am. Coll. of Gastroenterology.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.htmlen_US
dc.relation.ispartofAmerican Journal of Gastroenterologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAmoxicillin - Therapeutic Useen_US
dc.subject.meshAntacids - Therapeutic Useen_US
dc.subject.meshAnti-Bacterial Agents - Therapeutic Useen_US
dc.subject.meshBismuthen_US
dc.subject.meshDrug Therapy, Combination - Therapeutic Useen_US
dc.subject.meshDuodenal Ulcer - Complications - Drug Therapy - Pathologyen_US
dc.subject.meshEndoscopy, Digestive Systemen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHelicobacter Infections - Complications - Drug Therapy - Pathologyen_US
dc.subject.meshHelicobacter Pylori - Drug Effects - Isolation & Purificationen_US
dc.subject.meshHumansen_US
dc.subject.meshIntestinal Mucosa - Microbiology - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMetronidazole - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPeptic Ulcer Hemorrhage - Drug Therapy - Etiology - Pathologyen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRecurrence - Prevention & Controlen_US
dc.titleTreatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage - A long-term randomized, controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0002-9270(00)01041-8en_US
dc.identifier.pmid11007222-
dc.identifier.scopuseid_2-s2.0-0033835747en_US
dc.identifier.hkuros72208-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033835747&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume95en_US
dc.identifier.issue9en_US
dc.identifier.spage2225en_US
dc.identifier.epage2232en_US
dc.identifier.isiWOS:000089310400014-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, KC=7402135595en_US
dc.identifier.scopusauthoridHui, WM=7103196477en_US
dc.identifier.scopusauthoridWong, WM=7403972413en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridHu, WHC=7404359791en_US
dc.identifier.scopusauthoridChing, CK=7102130825en_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats